These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 7353370)

  • 1. An evaluation of 1 alpha-hydroxy-and 1,25-dihydroxyvitamin D3 in the treatment of renal bone disease.
    Kanis JA; Russell RG; Cundy T; Earnshaw M; Woods CG; Smith R; Heynen G
    Contrib Nephrol; 1980; 18():12-28. PubMed ID: 7353370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of calciferol and its metabolites on patients with chronic renal failure. II. Calcitriol, 1 alpha-hydroxyvitamin D3, and 24,25-dihydroxyvitamin D3.
    Voigts AL; Felsenfeld AJ; Llach F
    Arch Intern Med; 1983 Jun; 143(6):1205-11. PubMed ID: 6344827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of renal bone disease with 1 alpha-hydroxylated derivatives of vitamin D3. Clinical, biochemical, radiographic and histological responses.
    Kanis JA; Cundy T; Earnshaw M; Henderson RG; Heynen G; Naik R; Russell RG; Smith R; Woods CG
    Q J Med; 1979 Apr; 48(190):289-322. PubMed ID: 504552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of 1alpha(OH)D3 and 1alpha,25(OH)2D3 on the bone in patients with renal osteodystrophy.
    Bordier P; Zingraff J; Gueris J; Jungers P; Marie P; Pechet M; Rasmussen H
    Am J Med; 1978 Jan; 64(1):101-7. PubMed ID: 623125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased renal function in association with administration of 1,25-dihydroxyvitamin D3 to patients with stable, advanced renal failure.
    Christiansen C; Røodbro P; Christensen MS; Naestoft J; Hartnack B; Transbøol I
    Contrib Nephrol; 1980; 18():139-46. PubMed ID: 6243527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Skeletal response to treatment with 1,25-dihydroxyvitamin D in renal failure.
    Sherrard DJ; Coburn JW; Brickman AS; Singer FR; Maloney N
    Contrib Nephrol; 1980; 18():92-7. PubMed ID: 7353382
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-term effects of 1,25(OH)2D3 on clinical and biochemical derangements of divalent ions in dialysis patients.
    Goldstein DA; Malluche HH; Massry SG
    Contrib Nephrol; 1980; 18():42-54. PubMed ID: 7353379
    [No Abstract]   [Full Text] [Related]  

  • 8. Hemodialysis patients with a unique mineralizing defect unresponsive to 1,25-dihydroxycholecalciferol. Dialysis osteomalacic syndrome.
    Cameron EC; Prior JC; Ballon HS
    Contrib Nephrol; 1980; 18():162-71. PubMed ID: 6986229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical effects of 1,25-dihydroxyvitamin D3 in uremic patients with overt osteodystrophy.
    Brickman AS; Coburn JW; Sherrard DJ; Wong EG; Norman AW; Singer FR
    Contrib Nephrol; 1980; 18():29-41. PubMed ID: 7353378
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of hemodialysis bone disease with 24,25-(OH)2D3 and 1,25-(OH)2D3 alone or in combination.
    Dunstan CR; Hills E; Norman AW; Bishop JE; Mayer E; Wong SY; Eade Y; Johnson JR; George CR; Collett P
    Miner Electrolyte Metab; 1985; 11(6):358-68. PubMed ID: 3877862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vitamin D metabolites and bone mineralization in man.
    Bordier P; Rasmussen H; Marie P; Miravet L; Gueris J; Ryckwaert A
    J Clin Endocrinol Metab; 1978 Feb; 46(2):284-94. PubMed ID: 750606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of 1,25-dihydroxycholecalciferol in renal osteopathy].
    Reutter FW; Sieber R; Olah AJ; Dambacher MA
    Schweiz Med Wochenschr; 1979 Dec; 109(47):1880-3. PubMed ID: 531567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of a role for 1,25-dihydroxyvitamin D3 in the pathogenesis and treatment of X-linked hypophosphatemic rickets and osteomalacia.
    Drezner MK; Lyles KW; Haussler MR; Harrelson JM
    J Clin Invest; 1980 Nov; 66(5):1020-32. PubMed ID: 6253520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status of the use of 1,25(OH)2D3 in the management of renal osteodystrophy.
    Massry SG; Goldstein DA; Malluche HH
    Kidney Int; 1980 Oct; 18(4):409-18. PubMed ID: 7014981
    [No Abstract]   [Full Text] [Related]  

  • 15. Controlled trial of the effects of 1,25-dihydroxycholecalciferol in patients treated with regular dialysis.
    Berl T; Berns AS; Huffer WE; Alfrey AC; Arnaud CD; Schrier RR
    Contrib Nephrol; 1980; 18():72-81. PubMed ID: 6243528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of 1,25(OH)2-vitamin D3 to separate 'types' on renal osteodystrophy.
    Coburn JW; Brickman AS; Sherrard DJ; Singer FR; Wong EG; Baylink DJ; Norman AW
    Proc Eur Dial Transplant Assoc; 1977; 14():442-50. PubMed ID: 600961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors influencing the response to 1alpha-hydroxyvitamin D3 in patients with renal bone disease.
    Kanis JA; Russell RG; Naik RB; Earnshaw M; Smith R; Heynen G; Woods CG
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():51s-57s. PubMed ID: 606425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A skeletal mineralizing defect in dialysis patients: a syndrome resembling osteomalacia but unrelated to viatamin D.
    Coburn JW; Sherrard DJ; Brickman AS; Wong EG; Norman AW; Singer FR
    Contrib Nephrol; 1980; 18():172-83. PubMed ID: 7353374
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of 1,25(OH)2D3 and 24,25(OH)2D3 in the long-term treatment of renal osteodystrophy.
    Muirhead N; Catto GR; Edward N; Fraser RA; O'Riordan JL; Papapoulos SE; Adami S
    Proc Eur Dial Transplant Assoc; 1980; 17():543-7. PubMed ID: 6972529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1,25 dihydroxycholecalciferol effects in chronic dialysis. A double-blind controlled study.
    Berl T; Berns AS; Hufer WE; Hammill K; Alfrey AC; Arnaud CD; Schrier RW
    Ann Intern Med; 1978 Jun; 88(6):774-80. PubMed ID: 208439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.